IDH2 and central nervous system cancer: In the genetically engineered U87IDHmut model as well as in two patient-derived BT257 and SF10417 mutant IDH1 glioma models, treatments with either AG-881 or BAY-1436032 resulted in a consistent reduction in 2-HG, confirming brain penetration and action of the IDH inhibitors.